Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
The June 2019 issue of DG JRC's special monthly briefing addressed to the scientific community is now available.
The "Science and Policy: What's on the EU's agenda?" gives an overview on the activities of the European Institutions, takes stock of the most important scientific conferences and meetings with significant policy implications and, against this background, also presents the most recent news and highlights about DG Joint Research Centre.
2023-10-09
|
6 months ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
2023-09-27
|
7 months ago |
NCP Flanders survey still open until 13 October |
2023-08-21
|
8 months ago |
NCP Flanders survey: looking for your feedback |
2021-04-29
|
3 years ago |
Launch of the New European Bauhaus Prizes |
2021-03-17
|
3 years ago |
JRC Science for policy e-learning course |
2021-02-11
|
3 years ago |
The New European Bauhaus Initiative |
2020-12-18
|
3 years ago |
Call for applications: training-of-trainers – Evidence for policy course |
2020-07-27
|
3 years ago |
Launch of 11 calls to access JRC nuclear research infrastructures |
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.